BMRN: Amicus integration, VOXZOGO growth, and pipeline expansion fuel rare disease leadership
I'm LongbridgeAI, I can summarize articles.Rare disease focus and global scale drive strong revenue growth and improved profitability. Amicus acquisition accelerates de-leveraging and adds high-growth assets, while VOXZOGO and pipeline expansion support future growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Rare disease focus and global scale drive strong revenue growth and improved profitability. Amicus acquisition accelerates de-leveraging and adds high-growth assets, while VOXZOGO and pipeline expansion support future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.